Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




ACE Identified as Hemangioblast Regulator

By LabMedica International staff writers
Posted on 09 Sep 2008
A recent study described the discovery of a molecular switch that directs hemangioblasts--the most primitive form of blood cell--to differentiate into either angioblasts (endothelial cells) or hematopoietic (blood-forming) cells.

Investigators from Johns Hopkins University (Baltimore, MD, USA) reported in the August 26, 2008, online issue of the journal Blood that angiotensin-converting enzyme (ACE), a critical physiologic regulator of blood pressure, angiogenesis, and inflammation is a novel marker for identifying hemangioblasts in a pool of differentiating human embryonic stem cells (hESCs).

The investigators grew human embryonic stem cells in the presence of various growth factors over a period of 20 days. More...
They sampled individual cells, and selected those capable of making endothelial and blood cells, the hallmark of hemangioblasts. These cells were found to carry membrane-bound ACE. ACE served not only as a marker, but also played a regulatory role. Treatment of hemangioblasts with losartan, an ACE pathway-blocking agent routinely used to treat high blood pressure, dramatically increased the rate of blood cell production.

"We figured out how to get the ‘mother' of all blood stem cells with the right culture conditions,” said first author Dr. Elias Zambidis, professor of pediatric oncology at Johns Hopkins University. "There is real hope that in the future we can grow billions of blood cells at will to treat blood-related disorders, and just as critically if not more so, we have got ACE as a ‘new' old marker to guide our work. The next step is to test this research in animal models and show that we can make lots and lots of blood cells from human stem cells for transfusions, regenerate new vascular trees for heart diseases, as well as create test tube factories for making transplantable blood cells that treat diseases. We are very far from treatment, but this is a big step.”

Related Links:
Johns Hopkins University


Gold Member
Fibrinolysis Assay
HemosIL Fibrinolysis Assay Panel
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Hemodynamic System Monitor
OptoMonitor
Automated MALDI-TOF MS System
EXS 3000
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: The diagnostic device can tell how deadly brain tumors respond to treatment from a simple blood test (Photo courtesy of UQ)

Diagnostic Device Predicts Treatment Response for Brain Tumors Via Blood Test

Glioblastoma is one of the deadliest forms of brain cancer, largely because doctors have no reliable way to determine whether treatments are working in real time. Assessing therapeutic response currently... Read more

Immunology

view channel
Image: Circulating tumor cells isolated from blood samples could help guide immunotherapy decisions (Photo courtesy of Shutterstock)

Blood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug

Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more

Microbiology

view channel
Image: New evidence suggests that imbalances in the gut microbiome may contribute to the onset and progression of MCI and Alzheimer’s disease (Photo courtesy of Adobe Stock)

Comprehensive Review Identifies Gut Microbiome Signatures Associated With Alzheimer’s Disease

Alzheimer’s disease affects approximately 6.7 million people in the United States and nearly 50 million worldwide, yet early cognitive decline remains difficult to characterize. Increasing evidence suggests... Read more

Technology

view channel
Image: Vitestro has shared a detailed visual explanation of its Autonomous Robotic Phlebotomy Device (photo courtesy of Vitestro)

Robotic Technology Unveiled for Automated Diagnostic Blood Draws

Routine diagnostic blood collection is a high‑volume task that can strain staffing and introduce human‑dependent variability, with downstream implications for sample quality and patient experience.... Read more

Industry

view channel
Image: Roche’s cobas® Mass Spec solution enables fully automated mass spectrometry in routine clinical laboratories (Photo courtesy of Roche)

New Collaboration Brings Automated Mass Spectrometry to Routine Laboratory Testing

Mass spectrometry is a powerful analytical technique that identifies and quantifies molecules based on their mass and electrical charge. Its high selectivity, sensitivity, and accuracy make it indispensable... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.